7 results match your criteria: "Rokach Center for the Prevention of Lung Diseases[Affiliation]"
Eur Respir J
July 2020
Rokach Center for the Prevention of Lung Diseases, Clalit Health Services, Jerusalem Region, Affiliated to The Faculty of Medicine, Hebrew University and Hadassah, Jerusalem, Israel
https://bit.ly/36k2O2Q
View Article and Find Full Text PDFEur J Intern Med
October 2020
Rokach Center for the Prevention of Lung Diseases, Clalit Health Services, Jerusalem Region, Affiliated to The Faculty of Medicine, Hebrew University and Hadassah, Jerusalem, Israel; Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Electronic address:
Background: The characterization and clinical profiling of people affected by Idiopathic Pulmonary Fibrosis (IPF), based on clinical events occurring prior to the diagnosis of the fibrotic disease, may facilitate the understanding of events and comorbidities that occur before the diagnosis of IPF and aid in identifying patients at an earlier stage of the disease.
Methods: In this observational study, a cohort of 96 patients, obtained from a community-based pulmonary clinic, were studied retrospectively. These patients were diagnosed with IPF between January 2008 and November 2016, based on findings on lung biopsy and/or high-resolution CT.
F1000Res
June 2020
Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Air trapping and gas exchange abnormalities are major causes of exercise limitation in chronic obstructive pulmonary disease (COPD). During incremental cardiopulmonary exercise testing, actual nadir values of ventilatory equivalents for carbon dioxide (V /VCO ) and oxygen (V /VO ) may be difficult to identify in COPD patients because of limited ventilatory compensation capacity. Therefore, we aimed in this exploratory study to detect a possible correlation between the magnitude of ventilation augmentation, as manifested by increments in ventilatory equivalents from nadir to peak exercise values and air trapping, detected with static testing.
View Article and Find Full Text PDFBackground: Evidence for the effects of Parkinson disease on energy expenditure is incomplete and contradictory. A number of studies showed increased resting energy expenditure among patients with Parkinson disease whereas others did not. It was hypothesized that energy expenditure increases during exercise, based on findings in patients with a variable regime of anti-parkinsonian therapies and at different stages of the disease.
View Article and Find Full Text PDFAm J Cardiol
February 2017
Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rokach Center for the Prevention of Lung Diseases, Clalit Health Services, Affiliated to the School of Medicine, Hebrew University and Hadassah, Jerusalem, Israel. Electronic address:
The incremental cardiopulmonary exercise test (CPET) is an increasingly used diagnostic method that serves to evaluate patients with chief complaint of dyspnea during exercise. Performing maximal symptom-limited CPET can show if the tested subject has a reduced exercise capacity and give clues to the mechanism of such exercise capacity reduction, cardiac, pulmonary, or pulmonary vascular source. In this review, it is suggested that the evaluation of the complex results of CPET should be performed by first determining if myocardial/circulatory insufficiency is present and second if there is gas exchange abnormality.
View Article and Find Full Text PDFIsr Med Assoc J
September 2007
Rokach Center for the Prevention of Lung Diseases, Clalit Health Services, Jerusalem, Israel.
Isr Med Assoc J
July 2006
Rokach Center for the Prevention of Lung Diseases, Clalit Health Services, and Tuberculosis Treatment and Prevention Unit, Jerusalem, Israel.
Background: A publication bias exists towards positive results in studies funded by pharmaceutical companies.
Objectives: To determine whether drug studies in the pulmonary/allergy literature also demonstrate a publication bias towards more favorable results when a pharmaceutical company funds the study.
Methods: We reviewed all original articles published in seven pulmonary and allergy journals between October 2002 and September 2003.